Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JNJ-80038114
- Development stage
- Phase 1
- Lead developer
- Janssen Research & Development
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
JNJ-80038114 is a bispecific T-cell engager (BiTE) designed to redirect T-cells to target prostate-specific membrane antigen (PSMA)-expressing tumor cells. It binds both CD3 on T-cells and PSMA on prostate cancer cells, stimulating T-cell activation and cytotoxicity against the tumor. The drug is being developed by Janssen Research & Development for the treatment of metastatic castration-resistant prostate cancer (mCRPC). As of March 2025, it has completed Phase 1 clinical trials in patients with advanced stage or metastatic castration-resistant prostate cancer[1][3][5][6]. The agent is not yet approved for use in any country[7].
02
Targets
CD3 (T-cell surface glycoprotein CD3)PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on JNJ-80038114.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JNJ-80038114.